Tagged with BI

China Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated bispecific antibodies to meet unmet medical needs in China; shares the progress of their first program, EMB01, a EGFR-cMet bispecific…

France Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and oncology. Its most advanced program is a first-in-class drug candidate against NASH. Inventiva’s chairman, CEO and co-founder, Frédéric Cren, explains…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019.     Due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant The cannabis industry…

France Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave Big Pharma for biotech, lays out Inotrem’s recent milestones, and outlines his internationalization strategy.   The TREM-1 pathway can be…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

France Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities in the market.   Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO™ platform will be…

Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co.   Now that we have all this data,…

FT These insights come from Richie Etwaru, the CEO of Hu-Manity.co, known for pursuing the 31st Human Right “everyone has the right to legal ownership of their inherent human data as property.”    There is a tremendously broken data supply chain, which will trigger social uproar when the public are made…

China William Wei Cao, chairman and CEO of Gracell, shares the fascinating journey that inspired him to establish Gracell in Shanghai to tackle the four big challenges facing the global CAR-T industry; the four novel technology platforms Gracell is working on that are already drawing significant investor and Big Pharma interest;…

Korea YD Global Life Science is a Korean biopharmaceutical company with ambitions to become a global leader in new drug development with USD 1 billion in revenues. Its founder & CEO, Jin Woo Lee explains his strategy to reach this goal by licensing-out promising compounds acquired from research institutions, developing an…

France Christine Placet, CEO of French biotech Horama, discusses the objective of becoming one of the key players in the field of ophthalmic gene therapy. She explains how Horama’s unique pipeline can be a solution to unmet medical needs in retinal dystrophy and goes on to share her personal insights on…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…